JP7114702B2 - 新規置換キサンチン誘導体 - Google Patents

新規置換キサンチン誘導体 Download PDF

Info

Publication number
JP7114702B2
JP7114702B2 JP2020523041A JP2020523041A JP7114702B2 JP 7114702 B2 JP7114702 B2 JP 7114702B2 JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020523041 A JP2020523041 A JP 2020523041A JP 7114702 B2 JP7114702 B2 JP 7114702B2
Authority
JP
Japan
Prior art keywords
compound
mmol
trpc5
esi
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526591A (ja
JP2020526591A5 (https=
Inventor
カイ・ゲルラッハ
クリスティアン・アイクマイアー
アヒム・ザウアー
シュテファン・ユスト
バートランド・エル・チェナード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hydra Biosciences LLC
Original Assignee
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences LLC filed Critical Hydra Biosciences LLC
Publication of JP2020526591A publication Critical patent/JP2020526591A/ja
Publication of JP2020526591A5 publication Critical patent/JP2020526591A5/ja
Application granted granted Critical
Publication of JP7114702B2 publication Critical patent/JP7114702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020523041A 2017-07-11 2018-07-06 新規置換キサンチン誘導体 Active JP7114702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
EP17180721.7 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020526591A JP2020526591A (ja) 2020-08-31
JP2020526591A5 JP2020526591A5 (https=) 2021-08-12
JP7114702B2 true JP7114702B2 (ja) 2022-08-08

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523041A Active JP7114702B2 (ja) 2017-07-11 2018-07-06 新規置換キサンチン誘導体

Country Status (32)

Country Link
US (1) US10329292B2 (https=)
EP (1) EP3652176B1 (https=)
JP (1) JP7114702B2 (https=)
KR (1) KR102714554B1 (https=)
CN (1) CN110997675B (https=)
AR (1) AR112448A1 (https=)
AU (1) AU2018299824B2 (https=)
CA (1) CA3066922A1 (https=)
CL (1) CL2020000056A1 (https=)
CO (1) CO2019015102A2 (https=)
CY (1) CY1125014T1 (https=)
DK (1) DK3652176T3 (https=)
EA (1) EA039526B1 (https=)
ES (1) ES2903268T3 (https=)
HR (1) HRP20220029T1 (https=)
HU (1) HUE057600T2 (https=)
IL (1) IL271799B (https=)
LT (1) LT3652176T (https=)
MX (1) MX394089B (https=)
MY (1) MY200797A (https=)
PE (1) PE20200861A1 (https=)
PH (1) PH12020500079A1 (https=)
PL (1) PL3652176T3 (https=)
PT (1) PT3652176T (https=)
RS (1) RS62826B1 (https=)
SA (1) SA519410851B1 (https=)
SG (1) SG11201912168TA (https=)
SI (1) SI3652176T1 (https=)
SM (1) SMT202200013T1 (https=)
TW (1) TWI801398B (https=)
UA (1) UA124793C2 (https=)
WO (1) WO2019011802A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11623930B2 (en) 2018-03-05 2023-04-11 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
JP7502299B2 (ja) * 2018-12-12 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンチン誘導体
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513717A (ja) 2013-03-15 2016-05-16 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 置換キサンチンおよびその使用方法
JP2017523229A (ja) 2014-08-11 2017-08-17 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
JP2017524018A (ja) 2014-08-11 2017-08-24 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
AU2007274710A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513717A (ja) 2013-03-15 2016-05-16 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 置換キサンチンおよびその使用方法
JP2017523229A (ja) 2014-08-11 2017-08-17 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
JP2017524018A (ja) 2014-08-11 2017-08-24 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体

Also Published As

Publication number Publication date
HUE057600T2 (hu) 2022-05-28
PL3652176T3 (pl) 2022-04-04
JP2020526591A (ja) 2020-08-31
DK3652176T3 (da) 2022-01-17
PT3652176T (pt) 2022-01-13
MX394089B (es) 2025-03-24
EA039526B1 (ru) 2022-02-07
CL2020000056A1 (es) 2020-06-12
TWI801398B (zh) 2023-05-11
SG11201912168TA (en) 2020-01-30
EP3652176A1 (en) 2020-05-20
LT3652176T (lt) 2022-02-25
EA202090270A1 (ru) 2020-04-24
ES2903268T3 (es) 2022-03-31
PH12020500079A1 (en) 2020-10-05
NZ759728A (en) 2024-11-29
IL271799B (en) 2022-08-01
SMT202200013T1 (it) 2022-03-21
CN110997675A (zh) 2020-04-10
US10329292B2 (en) 2019-06-25
WO2019011802A1 (en) 2019-01-17
CO2019015102A2 (es) 2020-05-15
MX2020000402A (es) 2020-08-17
KR102714554B1 (ko) 2024-10-10
EP3652176B1 (en) 2021-12-15
US20190016722A1 (en) 2019-01-17
SA519410851B1 (ar) 2023-02-26
BR112019025611A2 (pt) 2020-06-16
CN110997675B (zh) 2022-06-07
CA3066922A1 (en) 2019-01-17
HRP20220029T1 (hr) 2022-04-15
SI3652176T1 (sl) 2022-04-29
IL271799A (en) 2020-02-27
CY1125014T1 (el) 2023-03-24
KR20200030048A (ko) 2020-03-19
RS62826B1 (sr) 2022-02-28
AR112448A1 (es) 2019-10-30
TW201908318A (zh) 2019-03-01
AU2018299824B2 (en) 2022-06-16
PE20200861A1 (es) 2020-08-25
AU2018299824A1 (en) 2019-12-19
MY200797A (en) 2024-01-16
UA124793C2 (uk) 2021-11-17

Similar Documents

Publication Publication Date Title
JP7114702B2 (ja) 新規置換キサンチン誘導体
JP7408662B2 (ja) 置換キサンタン誘導体
JP7502299B2 (ja) 置換キサンチン誘導体
CA3119229C (en) Substituted xanthine derivatives
HK40025200A (en) Substituted xanthine derivatives
HK40025200B (en) Substituted xanthine derivatives
BR112019025611B1 (pt) Compostos derivados de xantina substituídos e sais dos mesmos
EA043969B1 (ru) Замещенные ксантиновые производные

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210702

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220727

R150 Certificate of patent or registration of utility model

Ref document number: 7114702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250